DON AGRO INTERNATIONAL LIMITED

Registration No. 201835258H
(Incorporated in the Republic of Singapore)

1) MONTHLY VALUATION OF ASSETS AND UTILISATION OF CASH FOR THE MONTH OF MARCH 2025; AND

2) UPDATE OF MILESTONES IN OBTAINING NEW BUSINESS

The Board of Directors (the "**Board**" or the "**Directors**") of Don Agro International Limited (the "**Company"**) refers to the announcement released on the SGXNet on 8 July 2024 notifying shareholders of its cash company status pursuant to Rule 1017(1)(a) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist (the "**Catalist Rules**") and its previous announcement dated 28 March 2025 on the monthly updates.

Pursuant to Catalist Rule 1017(1)(b), the Board wishes to announce the following:

1. MONTHLY VALUATION OF ASSETS AND UTILISATION OF CASH FOR THE MONTH OF MARCH 2025

a) The Company's assets and liabilities as at 31 March 2025 were as follows:

	$'000
Assets	
Long -term investment	507
Trade and other receivables	37,602
Cash and cash equivalents	29,545
Total assets	67,654
Liabilities	
Trade and other payables	1,062
Current tax liabilities	84
Provisions	603
Total liabilities	1,749
Net assets	65,905

(b) The Company's utilisation of cash from 1 March 2025 to 31 March 2025 was as follows:

	RR'000[1]&[2]	**$'000**
Opening cash and bank balances as at 1 March 2025	4,233,957	63,954
Add receipts:		
Interest income from deposit	25,324	393
Foreign currency translation adjustment	-	2,492
Total receipts	25,324	2,885
Less payments**:**		
Bank charges and miscellaneous	(31)	(1)
Consideration Advance Payments in relation to Proposed Acquisitions	(2,220,000)	(34,495)
General and administrative expenses	(5,442)	(79)
Expenses relating to Proposed Acquisitions	(175,000)	(2,719)

[1] Relates to Russian subsidiaries of the Company and does not relate to the Company

[2] RR 66,22 to $ 1 as at 1 March 2025; RR 64,36 to $ 1 for March 2025; RR 62,93 to $ 1 as at 31 March 2025.

Total payments	(2,400,473)	(37,294)
Closing cash and bank balances as at 31 March 2025	**1,858,808**	**29,545**

All figures set out in this announcement have not been reviewed or audited by the Company's auditors.

2. UPDATE OF MILESTONES IN OBTAINING A NEW BUSINESS

As mentioned in the announcement dated 12 September 2024 in relation to the proposed acquisition of 812 Capital LLC and Centre for Innovative Medical Technologies, LLC (the "**Proposed Acquisition Announcement**"), that JSC Tetra, a wholly-owned subsidiary of the Company had, on 6 September 2024, entered into the agreements in respect of the proposed acquisition of 99.99% of the shares in 812 Capital LLC and 11.50% of the shares in Centre for Innovative Medical Technologies, LLC (together with their respective subsidiaries, the "**Target Group**").

The Target Group is a Russian network of expert oncology clinics operating under the "Euroonco" brand that provide a full range of cancer diagnostics and treatment. Entities operating under the Euroonco brand, focus primarily on providing a full range of cancer diagnostics and treatment services, as well as all types of antitumor and palliative treatment. Euroonco has expert oncology clinics and information and service centres in Moscow, Saint Petersburg, Nizhny Novgorod and Krasnodar. Please refer to the Proposed Acquisition Announcement for further details.

As announced on 21 January 2025, the Company had on 17 January 2025 received a letter from SGX-ST informing that SGX-ST has no objections to the Cash Utilisation Waiver, Escrow Requirement Waiver and Continued Trading Application ("**Waiver and Application Confirmation**") (the "**Waiver Announcement**") subject to the satisfaction of certain conditions (the "**Conditions**"). Please refer to the Waiver Announcement for further details.

As announced on 27 February 2025 the Group has released an announcement in relation to fulfillment of Conditions as stated in the Waiver and Application Confirmation. For details, please refer to announcement dated 27 February 2025 for further details.

On March 2025, the Consideration Advance Payments and payment of the CIMT Stake Consideration (as defined in the Proposed Acquisition Announcement) of RR 2,220,000,000 for proposed acquisition of medical business (equivalent to approximately S$34,495,000)[3] were remitted to Vendors (as defined in the Proposed Acquisition Announcement) after obtaining Waiver and Application Confirmation from SGX-ST on 17 January 2025 as mentioned above.

Also, the auditors and other consultants are still conducting an audit and due diligence procedures in accordance with SGX-ST requirements.

BY ORDER OF THE BOARD

Marat Devlet-Kildeyev
Chief Executive Officer and Executive Director
30 April 2025

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

[3] Based on the average exchange rate of S$1.00 = RR 64.36 for March 2025